Centre Antoine Lacassagne, Universite Cote d’Azur Finds Metformin No Help with Prostate Cancer

Centre Antoine Lacassagne, Université Cote d’Azur, Nice France reported on the TAXOMET trial results. They reported to ASCO that metformin, when added to docetaxel, has no impact on outcomes among patients with metastatic castration-resistant prostate cancer.

The Study

The first clinical trial to test the question of whether metformin can make a difference in outcome, the investigators noted that the drug fails to reduce prostate-specific antigen (PSA) levels any better than docetaxel along. Select the link to EurekAlert! for more details.

Lead Research/Investigator

Pujalte Martin, MD...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee